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1
TOWARDS STANDARDIZED REPORTING IN STUDIES OF  
ENCAPSULATING PERITONEAL SCLEROSIS
Encapsulating peritoneal sclerosis (EPS), a serious but uncommon complication of peritoneal dialysis 
(PD), initially well described in the Japanese patient 
population (1–3), is now widely recognized. Because of 
the severe morbidity and mortality attached, EPS has the 
potential to negatively affect perceptions of the value of 
PD as a long-term therapy and so affect the take-on rate 
and increase early transfer to HD. It is now well estab-
lished that EPS is strongly associated with duration of 
PD therapy (4,5), with ultrafiltration failure associated 
with membrane fibrosis (6,7), and also, paradoxically, 
with stopping PD. Nevertheless, significant deficits in the 
understanding of EPS remain. That lack of understand-
ing is implicit in nonspecific diagnostic criteria and an 
uncertain association with peritonitis, issues that arise 
in a study by Wong et al. (8) in this issue of Peritoneal 
Dialysis International.
WHAT ARE THE DIAGNOSTIC CRITERIA CURRENTLY, AND HOW 
HAVE THEY BEEN APPLIED?
The current International Society for Peritoneal 
Dialysis diagnostic criteria are set out in a review by 
Kawaguchi et al. (9) and are based on two factors: 
symptoms suggestive of bowel obstruction, and either 
surgical or radiologic evidence of peritoneal thickening 
or cocooning as a cause of the symptoms. Disturbance 
of normal intestinal function was emphasized, but clear 
obstruction was not specified as a necessity. Symptoms 
mentioned included abdominal pain, nausea, vomiting, 
weight loss, fullness, and anorexia, although the sever-
ity of these manifestations can be variable. Although 
the diagnosis at laparotomy is usually apparent, the 
radiologic criteria have subsequently been refined and 
evaluated in numerous studies. It is apparent from the 
published literature that application of these diagnostic 
criteria has varied considerably.
The largest case series of EPS comes from a retrospec-
tive London-wide “Pan-Thames” study, in which 33% of 
111 patients were reported to have obstruction; 67%, 
abdominal pain; 59%, vomiting; and 39%, ascites. Only 
20% were reported to have weight loss, but 39 of the 111 
were receiving parenteral nutrition. Mortality was 53%, 
with a median time to death of 7 months (10).
Summers et al. (11) published a single-center ret-
rospective case series from what is now one of the two 
designated UK surgical centers for EPS. Of 27 patients, 
16 had severe disease, with 6 cases of complete obstruc-
tion. The remaining 11 were classified as having “mild to 
moderate” disease, but the authors explicitly state that 
the division was arbitrary. Among the latter 11 patients, 
3 had features of EPS on computed tomography (CT), 
but with no symptoms; the others had symptoms not 
requiring surgery.
To minimize diagnostic heterogeneity in a Dutch series 
of 62 patients, only patients with persistent or recurrent 
obstruction together with radiologic or macroscopic 
evidence were included (12). In the single-center Stoke 
PD cohort, 2 of 11 patients with EPS were considered to 
present slightly differently, their EPS being associated 
with early and severe infectious peritonitis (6).
Based on a comparative analysis of CT images from 
27 EPS patients, 15 hemodialysis patients, and 20 PD 
patients with a mean dialysis duration of 4.0 years, a 
scoring system was developed based on quantifying 
the degree of 6 different findings. The resulting scores 
differentiated the groups well and produced good 
interobserver agreement; however, CT scores did not 
necessarily reflect disease activity (13).
In a review from Amsterdam of CT images, 15 patients 
with EPS were compared with 16 control subjects with 
a mean PD duration of 62 months (14). Of the control 
subjects, 10% or more showed peritoneal enhancement; 
12.5% or more, peritoneal calcification; and 18.7% or 
more, peritoneal thickening. Only 1 (6.3%) had obstruc-
tion. Notably, the authors considered non-resolving 
peritonitis to be an indicator of EPS. In another study 
of 20 EPS patients by Goodlad et al. (15), CT images 
from several months before a formal EPS diagnosis were 
reviewed. Compared with asymptomatic patients, those 
who were symptomatic had a significantly higher vali-
dated EPS CT score, but neither group was considered at 
the time to have EPS.
Several further studies have clearly identified patients 
with an abnormal pathologic process (sometimes associ-
ated with symptoms), among whom at least some have 
gone on to develop what the study authors consider 
to be “full-blown” EPS. However, because of the lack 
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of  more-specific diagnostic criteria, it is not possible 
to compare these groups because each study relied on 
the authors’ own perceptions of what constitutes “full-
blown” EPS.
WHAT IS THE ROLE OF PERITONITIS IN EPS?
Early publications frequently cite peritonitis as a risk 
factor for EPS, but the potential role that peritonitis 
might play in EPS is complex. First, peritonitis is a com-
mon reason for stopping PD, and stopping PD appears to 
be a risk factor. Second, a high frequency of peritonitis 
over a prolonged period might contribute to membrane 
damage accrued during long-term PD. Third, peritonitis 
might act as an acute precipitant of EPS (a “second hit”) 
in patients with fibrosed, damaged membranes. Fourth, 
EPS might present as a sterile peritonitis (an “inflam-
matory stage”), with or without an infectious trigger. 
And finally, EPS patients with ascites might develop 
spontaneous bacterial peritonitis.
The first issue is suggested by the fact that many case 
series report EPS more often developing after PD has 
stopped (10–12), possibly because of local accumulation 
of inflammatory or fibrotic signaling molecules. However, 
no studies have examined whether typical infectious 
peritonitis is over- or under-represented as a reason for 
stopping PD in patients who subsequently developed EPS 
compared with other patients without EPS matched for 
duration of PD.
The second issue has been examined most robustly in 
an ANZDATA study, in which peritonitis was not associated 
with EPS (16). That finding was replicated in other recent 
case series (6,11), with the EPS group actually having a 
significantly lower overall peritonitis rate in some cases 
(12). The likely reason for this counterintuitive finding 
may be the risk associated with stopping PD early if the 
peritonitis risk is higher.
The third issue has been only partially addressed in the 
past. A small study by Bilgic et al. (17) suggested that 
patients stopping PD for peritonitis were more likely to 
develop intra-abdominal collections, which themselves 
are associated with systemic inflammation; however, that 
study did not specifically address EPS. Another study 
by Szeto et al. (18) addressed intra-abdominal collec-
tions after peritonitis requiring catheter removal. In 24 
patients with available CT imaging, features compatible 
with EPS were present: peritoneal enhancement in 12.5%, 
peritoneal thickening in 45.8%, peritoneal calcification 
in 4.2%, bowel-wall thickening in 12.5%, adhesions in 
58.3%, and signs of obstruction in 16.7%. None of the 
patients were considered to have EPS despite the fact that 
2 were subsequently admitted with obstruction.
Very few published data are available to inform the 
fourth and final questions, aside from inferences from 
histologic work to address the fourth question.
WHAT DOES THIS LATEST STUDY ADD?
The single-center retrospective study by Wong et al. 
of 62 patients who had catheter removal for refractory 
peritonitis identified 39 “high risk” patients who were 
considered to have a persistent sterile peritonitis and 
23 others in whom peritonitis resolved after catheter 
removal and who acted as a control group. Evidence 
of persistent peritonitis included continued systemic 
inflammation and the presence of intra-abdominal col-
lections that were often bloodstained and always sterile 
on multiple paracenteses.
One important weakness of the study is its failure to 
report leukocyte counts in the collections (in EPS, blood-
stained ascites is usually free of leucocytes). Compared 
with the control group, the group designated high risk 
also had other features typically expected of an EPS 
cohort, with longer duration of PD, faster peritoneal 
solute transport rates, and most importantly, CT features 
and symptoms of EPS. Of the high-risk group, 12 went on 
to develop “full-blown” EPS at a mean of 37 days after 
catheter removal, and those 12 were compared with the 
rest of the high-risk group. No significant differences 
were found, although a trend toward faster solute trans-
port and ultrafiltration failure was observed in this study 
with very small numbers to support such an analysis.
The authors have therefore partly addressed the 
fourth question concerning the role of peritonitis in 
EPS by describing, with greater clarity than previously, 
a distinct presentation of EPS in which a non-resolving 
peritonitis is presumably precipitated by infectious 
peritonitis requiring catheter removal. Their patient 
group also had a relatively fast transition to obstructed 
EPS after catheter removal. The mean onset of 37 days 
is a finding similar to that in the London case series, in 
which the overall mean time to EPS after PD catheter 
removal was 5.5 months, but in which the progression to 
EPS occurred within 3 months for 17 of 20 patients whose 
catheter was removed for peritonitis.
Unfortunately, Wong et al. missed an opportunity to 
compare either their high-risk group or the “full blown” 
EPS subgroup to the rest of the EPS patients at their 
center, which would have helped to define how distinct 
their study group was. They could also have confirmed 
the culture-negative rate of the precipitating—presumed 
infectious—peritonitis.
What they have also done, however, is to also illustrate 
the variability in the diagnosis of EPS. The high-risk 
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group as a whole had a mean Tarzi CT score of 7.69, and 
all had symptoms compatible with EPS. Nevertheless, 
the authors felt that these factors were not sufficient 
to diagnose EPS. Based on existing case series, it seems 
highly likely that other authors would have described 
these patients as having EPS. As such, this study by Wong 
and colleagues could also be viewed as examining EPS 
patients for predictors of subsequent obstruction.
TABLE 1 
Suggested Structure for Reporting of Encapsulating Peritoneal Sclerosis (EPS)
 Domain Details
Radiologic  Computed tomography score as suggested by Tarzi et al. (see Table 2). It would be desirable to include 
the scores for each of the individual findingsa. The presence or absence of peritoneal enhancement 
should also be reported.
Macroscopic 1. Sticky fibrin coating lies atop the EPS membranes containing the brown and thick peritoneum, 
appearance of  with inter-enteric sclerotic membranes
encapsulation (19) 2. Cobweb-like inter-enteric sclerotic cover
 3. Classical intestinal cocooning with a sclerotic capsule
Intra-abdominal Sclerosis or tanning of small bowel:
extent (20) • Entire length or a section of bowel
 • Entire circumference or anti-mesenteric border
 Encapsulation:
 • Localized or widespread 
 Calcification: 
 • Isolated small plaques or large areas
Histologic Presence of
appearance (21) 1. Podoplanin 
 2. Fibroblast-like cells 
 3. Mesothelial denudation 
 4. Calcification 
 5. Acellular areas 
 6. Fibrin deposits 
 7. Fibrosis 
 8. Vasculopathy 
 9. Acute inflammation 
 10. Chronic inflammation
Symptomatology 1. Asymptomatic 
 2.  Mild symptoms (occasional pain, nausea, or even vomiting that does not require intervention or 
lead to a decline in nutrition)
 3.  Intermittent or mild-to-moderate obstructive symptoms (sufficient to contribute to undernutrition 
and weight loss—for example, because of food avoidance, pain, or episodes of vomiting that resolve 
without intervention) 
 4.  Complete or severe persistent obstructive symptoms that require intervention (surgery, drip and 
suck, parenteral nutrition)
Peritonitis or Report occurrence of any of
inflammation 1. Peritonitis causing cessation of peritoneal dialysis 
 2. Sterile prolonged peritonitis 
 3. Ascites without a raised white cell count 
 4. Significant systemic inflammation
a The computed tomography score proposed by Tarzi et al. (13) was selected because it provides more details on the areas it covers 
and because the division of bowel-wall thickening into small and large bowel by Vlijm et al. (14) produced scores that did not 
perform well at distinguishing EPS patients from control subjects, with poor consistency between observers. In the latter study, 
peritoneal enhancement did appear to perform well and so should also be reported.
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WHAT CAN WE DO ABOUT THE DIAGNOSTIC VARIABILITY?
Bearing in mind the large number of unanswered ques-
tions concerning EPS, there is a clear need to standardize 
the reporting of EPS cases so that it is clear which group 
of patients a study has incorporated and therefore how to 
interpret the findings. The easiest way of ensuring that 
cases of EPS are unequivocal is to stipulate that cases 
must have a severe form of obstruction—a strategy used 
by at least two recent studies, but likely to lead to under-
reporting of the problem, leaving many of the remaining 
questions concerning EPS unaddressed. For studies to 
be comparable and consistent, standardized reporting 
of details is necessary.
We suggest that studies should report all the findings 
covering the main features of EPS: that is, radiologic, 
surgical, and histologic findings; symptoms; the pres-
ence (or not) of peritonitis as defined by standard 
criteria; and local and systemic inflammation. Table 1 
sets out one potential structure that could be used. The 
structures for macroscopic appearance of encapsulation 
and intra-abdominal extent are based on work reported 
in this issue of Peritoneal Dialysis International (19,20), 
the radiologic structure is based on work by Tarzi et al. 
(10) and Vlijm et al. (14), and the histologic criteria are 
based on work by Braun et al. (21). As more data emerge, 
the structure can be refined iteratively.
We also suggest that studies should be quite clear, 
based on the foregoing features, which criteria they used 
to diagnose EPS: that is, the CT score or the criteria used 
if radiologic findings were considered important, how the 
presence of peritonitis was viewed, the level of symptoms 
that were considered necessary, and whether surgical 
findings were considered important, with a clear descrip-
tion of what was considered EPS based on the outlined 
structure. Furthermore, given that the natural history of 
EPS is still not exactly clear, we recommend that studies 
stipulate whether the diagnostic criteria were applied 
based on i itial presentation or subsequent progression. 
If the diagnosis was not made at initial presentation, then 
information on which of the EPS features were present at 
that time should also be provided, if available.
We believe that this kind of approach will allow for a 
clearer picture of the natural history of EPS to emerge 
and for better comparability between studies. It will also 
provide a structure to investigate issues such as the role 
of inflammation.
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